These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6110654)

  • 1. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients.
    Carman JS; Bigelow LB; Wyatt RJ
    J Clin Psychiatry; 1981 Mar; 42(3):124-8. PubMed ID: 6110654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptics and reserpine in refractory psychoses.
    Berlant JL
    J Clin Psychopharmacol; 1986 Jun; 6(3):180-4. PubMed ID: 2872238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complications of combined use of lithium salts and neuroleptics in patients with endogenous psychoses].
    Mosolov SN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(3):115-21. PubMed ID: 6134409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder.
    Small JG; Klapper MH; Malloy FW; Steadman TM
    J Clin Psychopharmacol; 2003 Jun; 23(3):223-8. PubMed ID: 12826983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
    Lerner V; Libov I; Kotler M; Strous RD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C; Cohen H; Kotler M; Lerner V
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J; Kaplan Z; Benjamin J
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acutely psychotic patients: a treatment approach.
    Wagemaker H; Lippmann S; Cade JR
    South Med J; 1985 Jul; 78(7):833-7. PubMed ID: 2861662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of neuroleptic psychopharmacology.
    Ortiz A; Gershon S
    J Clin Psychiatry; 1986 May; 47 Suppl():3-11. PubMed ID: 2871013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
    Ritsner MS; Gibel A; Shleifer T; Boguslavsky I; Zayed A; Maayan R; Weizman A; Lerner V
    J Clin Psychiatry; 2010 Oct; 71(10):1351-62. PubMed ID: 20584515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of pinpointing mood swings in expanding the indications for lithium salts in schizophrenic psychosis].
    Capdeville C; Darcourt G
    Ann Med Psychol (Paris); 1987 Jan; 145(1):78-82. PubMed ID: 2886087
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of schizoaffective disorders.
    Goodnick PJ; Meltzer HY
    Schizophr Bull; 1984; 10(1):30-48. PubMed ID: 6142525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
    Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients.
    Gaertner I; Gilot C; Heidrich P; Gaertner HJ
    Pharmacopsychiatry; 2002 Mar; 35(2):37-43. PubMed ID: 11951144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.